
Molnupiravir - Covid-19
You are here : Home > Formulary Search > Molnupiravir - Covid-19
Status 1
- Capsules
Primary care and outpatient prescribing of antivirals for COVID 19 treatment is through the CMDU service.
Hospital inpatients - as per local hospital guidelines
Documentation
PAD Profile
Committee Recommendations (1)
The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed that molnupiravir (Lagevrio) should be made available in line with NICE TA1056 for the treatment of COVID-19 for people who are at highest risk of becoming seriously ill as defined in section 5 of NICE's technology appraisal guidance on nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 only if both nirmatrelvir plus ritonavir and sotrovimab are contraindicated or unsuitable.
It is considered as a RED drug and should only be prescribed by individuals who have been assessed by the Covid Medicines Delivery Unit (or if a patient who falls into one of the highest-risk cohorts is in hospital and gets COVID-19 whilst an inpatient). Not for prescribing through A&E / hospital clinics.
Other Indications
Below are listed other indications that Molnupiravir is used to treat.
- No records returned.
Other Drugs
Below are listed other drugs that are used to treat Covid-19.